A5015961944- Genital Health and Disease
- Urologic and reproductive health conditions
- Sexuality, Behavior, and Technology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Autoimmune Bullous Skin Diseases
- Sarcoma Diagnosis and Treatment
- Sexual function and dysfunction studies
- Systemic Sclerosis and Related Diseases
- Hormonal and reproductive studies
- Cardiac tumors and thrombi
- Colorectal and Anal Carcinomas
- Urological Disorders and Treatments
Sparsh Hospital
2022
Institute of Medical Sciences and Sum Hospital
2021
Center for Rheumatology
2018
Objective To compare the efficacy and safety of avanafil as compared with sildenafil in management patients erectile dysfunction. Methods It was a prospective, randomized, double‐blind, two‐arm, active‐controlled, parallel, multicenter, non‐inferiority clinical study carried out dysfunction for at least 3 months International Index Erectile Function – domain score <26 enrolment. Results A total 220 were randomized to receive either tablets 100 mg or 50 1:1 ratio. After 4 weeks treatment,...
Abstract Objectives Penile squamous cell carcinomas (PCs) are rare malignancies with a dismal prognosis in metastatic setting; therefore, novel immunotherapeutic modalities an unmet need. One such modality is the immune checkpoint molecule programmed death ligand 1 (PD-L1). We sought to analyze PD-L1 expression and its correlation various clinicopathologic parameters contemporary cohort of 134 patients PC. Methods A PC was studied for immunohistochemistry. The evaluated using combined...
Primary renal synovial sarcoma is a rare aggressive mesenchymal neoplasm of the kidney that accounts for less than 1% sarcomas. Herein, we describe clinicopathologic and molecular findings 14 patients in one largest case series to date our knowledge, only use novel SS18-SSX IHC. Clinicopathologic, IHC, molecular, management, follow-up data were reviewed analyzed. Macroscopically, tumors had either homogeneous, tan-white, solid ( n = 10), variegated 3), or solid-cystic 1) cut surfaces....
<h3>Background</h3> Systemic sclerosis is characterised by fibrotic changes in the skin and lung, mainstay of treatment has been cyclophosphamide. B cell involvement suggests that rituximab may also be therapeutic benefit. In this study, we compared safety efficacy to cyclophosphamide lung manifestations systemic sclerosis. <h3>Objectives</h3> The aims study were assess IV Rituximab cyclophopsphamide primary therapy sclerosis, with particular emphasis on pulmonary dermatological...